01614nam a2200229   4500001000800000005001700008007000300025008004100028040000800069041000800077100002800085245004700113300002500160520098200185650001201167650001901179650002101198650002801219650001601247700001801263773010301281ESSALUD20260805002026.0ta      t        pe ||||| |||| 00| 0 spa d  aBMG  aeng  aDu Toit, George eAutor  aPrevention and treatment of peanut allergy  apáginas: 2449-2458  aEarly introduction of peanut protein reduces allergy prevalence by approximately 80%, with efficacy diminishing as introduction is delayed. Appropriate prevention involves ingestion of approximately 2 g of peanut protein weekly for infants at low risk and 4 to 6 g weekly for infants at high risk. Population-level implementation that targets all infants achieves greater reduction in disease burden than approaches that target only high-risk groups, although disparities exist among some ethnic groups and groups with restricted access to care. Peanut immunotherapy initiated in younger children (1 to 3 years of age) shows superior efficacy and higher rates of clinical remission as compared with immunotherapy initiated in older children. The natural history of untreated peanut allergy follows a trajectory of increasing peanut-specific IgE levels and clinical reactivity over time, underscoring the importance of early intervention during this narrow developmental window.  aALERGIA  aDERMATOLOGÍA  aMEDICINA CLINICA  aENFERMEDADES INFANTILES  aNUTRICIÓN  aLack, Gideon 0 022717dMassachusetts NEJM GroupoNEJM006tThe New England Journal of Medicine wESSALUDx0028-4793